Abstracts tagged "inflammation and respiratory disease"

Abstract Number: 358 • 2018 ACR/ARHP Annual Meeting
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Sang Kim¹, Vickie Shannon², Ajay Sheshardi², Hagop Kantarjian³, Guillermo Garcia-Manero³, Farhad Ravandi³, Aung Naing⁴, Padmanee Sharma⁵, Jin Im⁶, Wilfredo Ruiz Vazquez⁶, Adi Diab⁷, Dimitrios Kontoyiannis⁸, Andrew Futreal⁹ and Naval Daver³, ¹General Internal Medicine, MD Anderson Cancer Center, Houston, TX, ²Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, ³Leukemia, MD Anderson Cancer Center, Houston, TX, ⁴Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, ⁵Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, ⁷Melanoma Medical Oncology, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁸Infectious Diseases, MD Anderson Cancer Center, Houston, TX, ⁹Genomic Medicine, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].